Cancer Research

Article	Citations
Cancer Research in the Age of Big Data	867
Abstract 6922: MDM2 inhibitor alrizomadlin induces ferroptosis through p53 dependent and independent pathways in TP53 wildtype NSCLC	246
Abstract P84: Sorted cell populations with epigenetically silenced chromosomally dispersed reporter fluorophore gene as a test-system for the screening of non-genotoxic carcinogens	186
Abstract IA002: Full circle: Return of value to ovarian cancer research participants, advocates, and survivors	175
Abstract IA025: AI-powered discovery of biomarkers from histopathological images in ovarian cancer	160
Abstract B058: VEGF inhibition enhances immune checkpoint blockade efficacy in ovarian cancer	150
Abstract PR004: Phase 2 study of the PD-L1 inhibitor durvalumab and VEGFR inhibitor cediranib combination with and without PARP inhibitor olaparib in patients with recurrent ovarian cancer	144
Abstract A051: Targeting notch signaling pathway with auranofin for endometrial cancer therapy	133
Abstract A029: PARP-targeted alpha therapy for the treatment of PARP inhibitor resistant ovarian cancer	130
Abstract B039: Application of unsupervised clustering to whole slide images of high-grade serous ovarian cancer predicts prognosis	129
The Approaching Darwinian Era in Oncology	126
Abstract P51: MCL-1 safeguards activated hair follicle stem cells to enable adult hair regeneration	124
Abstract P30: Targeting B7-H3 Positive Solid Tumor Malignancies with Chimeric Antigen Receptor Epstein-Barr Virus Specific T Cells Armoured with An Engineered SerpinB9 Molecule for Improved Persistenc	123
Abstract P56: Suppression of Breast Cancer Growth via Inhibition of c-Myc Expression by RUNX3	120
Abstract A050: Truncated PPM1D cooperates with the PI3K pathway to drive Diffuse Midline Gliomas	118
Abstract B031: Uncovering genetic and regulatory drivers of tumor-specific splicing in pediatric brain tumors	108
Abstract A002-PR011: Precision Diagnosis in High-Risk Pediatric Oncology through Integrated Whole Genome, Transcriptome, and Epigenome Profiling	107
Abstract 4286: CHK1 as a novel therapeutic target for pleural mesothelioma	106
Abstract 3358: Tertiary lymphoid structures (TLS) estimated by AI tools from digital H&E slides significantly enhance survival prediction in high-risk AJCC stages III/IV melanoma	106
Abstract A027: Combined AKT and XPO1 Inhibition to Target Chimeric Transcription-Factor Driven Pediatric Sarcoma Pathogenesis	105
Abstract A021: CLK inhibition induces mis-splicing of SOX8 in alveolar rhabdomyosarcoma	101
Abstract IA003: Intersecting Developmental and Oncogenic Networks in ZFTA Fusion-Driven Brain Cancer	99
Abstract 2651: Nuclear prothymosin α suppresses TGF-β-induced EMT by stabilizing smad7: implications for lung cancer progression and metastasis	99
Abstract IA005: Fetal barriers to fusion protein-driven leukemogenesis	99
Abstract 1701: Investigating trastuzumab-deruxtecan (DS-8201) resistance mechanisms using clinically relevant PDX models and combination strategies with anti-PD-1 antibody	98

Abstract A068: A phase 2 study to investigate the efficacy and safety of acoustic cluster therapy with modified FOLFIRINOX in patients with locally advanced pancreatic cancer	97
Abstract A117: Co-priming sonic hedgehog inhibitor sonidegib with plerixafor induces tumor microenvironment transformation that enhances fluorescent nanoparticle deposition in pancreatic tumor xenogra	96
Abstract A035: KMT2D Loss Induces Enrichment of Plod2+ Fibroblasts in Pancreatic Cancer	94
Neuroblastoma Differentiation: The Untapped Potential of Mitochondrial Uncouplers	94
Abstract A027: HuR drives immune evasion, metastases and KRAS addiction in pancreatic ductal adenocarcinoma: implications for IO-based and KRAS inhibitor therapies	94
Abstract 524: An integrative approach to unveiling biomarkers and therapeutic targets identifies novel treatment strategy for advanced prostate cancer	93
Abstract 515: Repurposing nebivolol with dasatinib and CPI-613: A synergistic strategy to combat triple-negative breast cancer	91
Abstract 115: S-adenosyl-methionine (SAM) synthesis protects ovarian cancer from chemotherapy induced DNA damage and contributes to cancer stem cell enrichment	90
Abstract 691: Decentralized pan-cancer tumor profiling: a comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDMTM	90
Abstract 817: A prospective, multi-center, phase IV study to evaluate safety and efficacy of Dr. Reddy’s bevacizumab (DRL_BZ) in patients with solid tumors	90
Abstract 365: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma	89
Abstract 1108: Tissue and circulating DNA methylation profiling can recapitulate SCLC heterogeneity to enable identification of new biomarkers of clinical relevance	89
Abstract 244: Identification of proteins in the oncogenic FLT3-ITD signaling pathway using the APEX2 system	89
Abstract 1066: OncoKBTM, MSK’s precision oncology knowledge base: 2024 updates	87
Abstract 6063: ROSE12, a novel anti-CTLA-4 Switch antibody™ with FcγR affinity-enhanced Fc, evokes tumor-selective anti-tumor immune activation by extracellular ATP without systemic immune activation	85
Abstract 1520: Obesity delays melanoma resistance to BRAF/MEKi inhibitors and alters melanoma metabolism	85
Abstract 6096: Acquired CAR-T therapy resistance in a pre-clinical model of pediatric rhabdomyosarcoma minimal residual disease	84
Abstract 5726: QLS1103, A highly potent and selective PARP7 inhibitor treating advanced solid tumors	84
Abstract 6095: T-PureTM: A bispecific antibody cocktail for T cell isolation from human blood, enabling simple and affordable point-of-care CAR-T manufacturing	84
Abstract 5166: Increasing translatability of syngeneic mouse models of cancer through the application of human-validated, clinically relevant gene expression-based measurements of the tumor immune mic	82
Abstract 4822: Efficacy of 4-1BB-costimulated NKG2D CAR-T cells for synovial sarcoma in comparison with CAR-T cells targeting other antigens	82
Abstract 7205: Targeting diverse pathways for the treatment of KRAS driven non-small cell lung cancer	79
Abstract 7326: ATG-201, a novel T-cell engager (TCE) effectively depletes B cells with reduced risk of CRS for the treatment of B cell malignancies and B cell related autoimmune diseases	79
Abstract 7446: Stratification of cell therapies in solid tumor organoids using deep learning-derived imaging metrics	78
Abstract 7180: DNA methylation profiling of peripheral blood mononuclear cells from small-cell lung cancer patients treated with hypomethylating agent plus carboplatin	78
Abstract 7388: Trends of diagnosis disclosure among individuals with plasma cell disorders	76
Abstract 7374: Body size and composition in relation to PI3K/AKT/mTOR signaling: insights into cancer risk and outcomes - a systematic review	75
Abstract 4454: Cancer cell permeability induced by tumor treating fields (TTFields) improves chemotherapy uptake and requires cells to transverse through the G2/M phase under TTFields application	73
Abstract 6271: Interactions between CD8+ T cells and tumor cells decode tumor heterogeneity and provide treatment recommendations for colorectal cancer	73
Abstract 7211: Proteolysis targeting chimeras (PROTACs) of oncogenic RET protein	73
Abstract 5365: Comparison of whole genome sequencing and target capture sequencing in lung cancer	73
Abstract 7131: Integrative single-cell transcriptomic and epigenomic immune profiling reveals parallel insights into cancer research	73
Abstract 4575: mRNA expression in paired saliva and blood samples from different cancer indices	73
Abstract 140: Profiling ECM biomarkers PRO-C3 and PRO-C5 in plasma from patients with esophagogastric cancer	71
Abstract 3434: Evaluation of TCR-engineered T cells specific for KRAS G12V mutant peptide presented by HLA-A*02:01	71
Abstract 2119: Targeting KIT in chromophobe renal cell carcinoma	70
Abstract 1348: Investigation of sex disparity in hepatocarcinogenesis using a hydrodynamic tail vein injection mouse model	69
Abstract 88: Ephrin receptor A4 is a regulator of metastatic colonization in triple negative breast cancer	69
Abstract 2804: Long non-coding RNA LINC01614 regulates ferroptosis-mediated carcinogenic phenotypes in papillary thyroid cancer	68
Abstract 6198: Framework for Pacific Island Cancer and Obesity Across the Lifespan: PICOLI, A multi-dataset analysis approach	68
Abstract 3915: An orthotopic model for murine urothelial carcinoma with response to standard of care checkpoint inhibitor treatment	67
Abstract 2056: Development of a response prediction Model for venetoclax-based therapy utilizing molecular interactions among BCL2 family members	67
Abstract 904: Mapping the T cell-cold phenotype to the colorectal cancer genome identifies POFUT1 as a driver of tumor T cell inhibition	66
Abstract 1719: Constitutive aryl hydrocarbon activity promotes resistance to bortezomib which is exacerbated by leptin and potentially involves Src phosphorylation by JAK2 in prostate cancer cells	66
Abstract 4173: Compensatory interactions between tryptophan catabolism and serine metabolism highlight potential vulnerabilities in TNBC cells with dysregulated de novo serine synthesis	66
Abstract 5105: Tumor treating fields (TTFields) alter nanomechanical attributes of cell-ECM complex in pancreatic ductal adenocarcinoma	66
Abstract 988: Impact of the COVID-19 pandemic on HPV vaccine hesitancy	65
Abstract 72: A case of immune therapy-refractory composite lymphoma: The complex interplay between two distinct tumors within a single spatial microenvironment	64
Abstract 713: Utility of next generation sequencing multigene assay for comprehensive molecular profiling and targeted therapy in solid organ malignancies - An Indian experience	64
Abstract 1168: ADAR1 synthetic lethality in BRCA1/2-mutant tumors defines autocrine interferon poisoning as a targetable vulnerability of cancer cells	64

Abstract 1470: Inhibition of protein myristoylation sensitizes pancreatic cancer cells to DNA damage agents	63
Abstract 3045: Development of a first-in-class PDIA6/IRE1 modulator for selectively sensitizing cancer cells to ER stress and regulated cell death	63
Abstract 1086: Introducing the Florida Cancer Research (FL CARES) Network and the Platform for Accelerating Collaborative Computational Cancer Research (PAC3R)	61
Abstract 2485: A Bayesian framework for unraveling disease biology from spatially resolved single-cell omics datasets by combining unbiased approaches with biological priors for cell-based microdomain	61
Abstract 2486: Decoding tumor evolution through fitness landscapes of aneuploid cells	61
Abstract CT072: First in human trial of Q702 in patients with advanced solid tumors	61
Abstract CT115: Phase 1b open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in combination with sintilimab (anti-PD1) in patients with advanced microsatellite stable (MSS)	60
Abstract LB070: Trefoil factor I (TFF1) as a modulator of intrinsic and stroma induced chemoresistance in pancreatic ductal adenocarcinoma	60
Abstract LB025: Spatiotemporally regulated expression of membrane-bound interleukin 12 (mbIL12) for armored adoptive cell therapy (ACT) shows strong antitumor activity in syngeneic solid tumor models	60
Abstract LB197: Efficacy, safety, and protein markers of PD-1 inhibitors plus metronomic oral vinorelbine in elderly metastatic non-small-cell lung cancer patients	60
Abstract LB306: 3D epigenomic analysis reveals non-coding DNA regions that can reverse prostate cancer phenotypes	59
Abstract LB452: The role of dysregulated retinoid receptors in colorectal cancer	59
Abstract LB084: Fzd7 promotes melanoma growth via fostering an immunosuppressive tumor microenvironment	58
Abstract LB323: Thioredoxin interacting protein (TXNIP), a regulator of oxidative stress, mediates the RAPGEF3/4 (EPAC1/2) signaling required for melanoma progression	57
Abstract LB149: Predicted gut microbial metabolites and chemotherapy induced toxicity among breast cancer patients	57
Abstract LB247: Effects of health insurance on survival for five common cancers in China: A multicenter, hospital-based, retrospective cohort study	57
Abstract 2670: Understanding cell-of-origin influence on cancer-associated fibroblasts in lung adenocarcinoma	56
Abstract 1632: EGFR-TKIs facilitate cuproptosis via regulating SLC31A1 in cancer cells	56
Abstract SY22-03: Multifaceted mitochondria in the regulation of chromosome inheritance	56
Abstract 5017: A multimodal deep learning approach to predict survival in never smoking lung cancer patients	56
Abstract LB309: Differential DNA methylation analysis and functional insights in luminal A and triple-negative breast cancer using FFPE samples	56
Abstract 5956: Glioblastoma in Appalachia: A retrospective analysis	56
Abstract 2250: UCHL1 hijacks tolerogenic DC maturation and promotes mregDC-Treg crosstalk to nullify anti-PD-L1 therapy	54
Abstract 2933: IDP-001 is a potent bispecific ADC with in vivo activity against mouse xenograft tumor models expressing EGFR and CDCP1	54
Abstract 6297: Mapping cellular interactions from spatially resolved transcriptomics data	54
Abstract 6327: Prevention of glioblastoma cell growth by Vialinin A	54
Abstract 5131: Dysregulated cholesterol metabolism facilitates epithelial-to-mesenchymal transition and tumor progression in colorectal cancer	53
Abstract 3997: Advancing precision cancer medicine with patient-derived organoids: an endometrial cancer case study	53
Abstract 3848: Smoking promotes angiogenesis and epithelial to mesenchymal transition in breast cancer	53
Abstract 5887: NALCN promoter methylation as a biomarker for metastatic risk in a cohort of non-small cell lung cancer patients	53
Abstract 5333: CDK4/6 inhibitors in patients with bone-only metastatic breast cancer, the role of immune microenvironment	52
Abstract 2028: Development of a miRNA-based prognostic signature for clear cell renal cell carcinoma	52
Abstract 1783: Harnessing macrophage-drug conjugates for allogeneic cell-based therapy of solid tumors	52
Abstract 3216: A dual-acting chimeric peptide inhibits tumor growth by inhibiting PD-L1 and inducing immunogenic cell death	52
Abstract 6065: Preclinical evaluation of LM-168: A next-generation anti-CTLA4 antibody with promising efficacy and reduced toxicity	52
Abstract 7092: The change in Asian American/Native American/Pacific Islander demographics in interventional clinical trials in Hawai'i	51
Abstract 7306: Selective and novel ALDH1 inhibitor enhances immune checkpoint blockade therapy in preclinical models of MSS colorectal cancer	50
Abstract 6826: PRMT5 inhibition is a promising therapeutic strategy for high-risk neuroblastoma	50
Abstract 3842: ZNF217 promotes breast tumor progression by facilitating angiogenesis	50
Abstract 6762: Baseline multiomics and chemotherapy efficacy in preclinical trials using patient-derived xenograft models of cholangiocarcinoma can reveal distinct signatures of chemotherapy response	50
Abstract 6337: A novel PMS2 mutant Lynch syndrome mouse model for cancer prevention studies	50
Abstract 6302: A CellProfiler pipeline for RNAscope analyzing multiple markers across adjacent tissue sections spatially	50
Abstract 5379: NNMT loss drives prostate cancer progression through epigenetic and metabolic reprogramming	50
Abstract 6310: Bridging spatial proteomics and classical histopathology: advanced spatial analysis through H&E-enhanced multiplexed immunoprofiling	49
Abstract 4862: Targeting fli1 improves antitumor response of CD8 T cells by promoting their activation and limiting exhaustion	49
Abstract 5671: Development of HTS enzymatic assays for VPS4A and related ATPases	49
Abstract 5649: Potentiation of AKR1C3- and P53-dependent AST-3424 activity via PUMA-mediated degradation of Rad51	49
Abstract 5708: Investigating the role of SMYD3 in medulloblastoma progression and treatment response: Implications for targeted therapy	49
Abstract 6991: Targeting NONO as a therapeutic strategy for metastatic castration-resistant prostate cancer (CRPC)	48
Abstract 6880: Rinatabart sesutecan (PRO1184) in combination with standard-of-care therapy exerted potentiated antitumor activity in preclinical cancer models	48
Abstract 6996: Integrating high-throughput screening with ligand-based pharmacophore modeling and virtual screening strategies to optimize exonuclease 1 inhibitor design	48
Abstract 4867: Enhancing TCR-T with a Fas-based switch receptor boosts T cell engraftment, persistence, and anti-tumor activity in models of hard-to-treat PRAME solid tumor indications	48
Abstract 4002: Development of an organoid coculture model to investigate tumor immune interactions and therapeutic strategies in prostate cancer	48
Abstract 6939: MAPKAP kinase 2 regulates inflammatory responses in glioblastoma	48
Abstract 3514: AZD6621: Improving the therapeutic index for prostate cancer T cell engagers with a next-generation CD8-guided format	48
Abstract 7449: Evaluating the effectiveness of machine learning models using polygenic risk scores and clinical factors for breast cancer risk stratification	48
Abstract 3824: Investigating the role of allelic imbalance in pancreatic cancer aggressiveness, survival, and therapeutic resistance	47
Abstract 7229: Humanized mouse models of γδ T engraftment for the testing of cell based anti-cancer therapeutics	47
Abstract 3163: Discovery of highly selective ligands for the Bcl-2 family of proteins using DNA-encoded chemical libraries	47
Abstract 5774: Enhancing urothelial carcinoma treatment with nectin-4-PET: A predictor of enfortumab vedotin efficacy	47
Abstract 4653: Platelet to lymphocyte ratio and platelet count: new frontiers as prognostic factors in metastatic colorectal cancer patients receiving anti-angiogenic drugs	47
Abstract 5544: Identification, isolation and molecular characterization of drug-resistant sub-populations of pancreatic cancer cells	46
Abstract 3810: Targeting the ADAR1/PKR pathway in TP53-mutant acute myeloid leukemia	46
Abstract 4014: Prognostic evaluation of breast cancer long-term survival outcomes: contributions from a Brazilian hospital-based cohort	46
Abstract 1762: Preclinical and clinical studies of PEP07, a novel brain penetrating oral Chk1 inhibitor, on AML and MCL treatments	45
Abstract 1504: Harnessing the power of mangifera indica: Activation of Nrf2 by leaf-derived oxylipins	44
Abstract 3224: An indirect Meta-analysis of efficacy and safety of PD-1 inhibitors versus PD-L1 inhibitors as preoperative therapy in patients with solid tumors	44
Abstract 5778: Intra-operative visualization of metastatic sentinel lymph nodes in early breast cancer: An approach to omission of axillary surgery	44
Abstract 2405: NGS-based molecular profiling reveals remarkable anticancer synergy of EZH1/2 dual inhibitor HM97662 with standard-of-care therapy on small cell lung cancer	43
Abstract 5753: Multi-omic analysis links neighborhood disadvantage to elevated stress hormones and tumorigenic markers in ER+ breast cancer patient plasma and tumor samples	43
Abstract 4831: DNA methylation of immune synapse genes drives tumor immune evasion	43
Abstract 242: Differential activation of TAM receptors by Gas6 and protein S	42
Abstract 4217: Effect of HDAC3 targeting on endometrial cancer progression and therapeutic potential	42
Abstract 5755: Expansion of the known functional diversity of human T cells achieved due to the unprecedented resolution of intracellular proteins by mass cytometry (CyTOF)	42
Abstract 3510: A 2+1 format MUC16 targeting T cell engager induces MUC16-dependent T cell activity and superior anti-tumor efficacy	42
Abstract 1843: Therapeutic implication of pH/hypoxic responsive nanoencapsulated tunicamycin on pancreatic cancer by targeting K-RasG12D	42
Abstract 2696: Targeting SLC7A11 creates a favorable immune microenvironment in colorectal cancer	42
Abstract 2232: BGB-R046, an IL-15 pro-drug demonstrates robust pharmacodynamic effects and immune activation within tumor microenvironment in a mouse syngeneic model	42
Abstract 3005: Discovery of a potential therapeutic mechanism for selected tumors via targeting PI3K and DDR pathways simultaneously with a novel orally available small molecule	42
Abstract 1718: Role of IKKε in resistance to second-generation hormone therapy in prostate cancer	41

Abstract 3603: Racial and ethnic disparities in colorectal cancer-specific mortality: The Multiethnic Cohort	41
Abstract 4192: Preclinical characterization of LAE122, a novel, potent and selective WRN inhibitor for the treatment of MSI-H tumors	41
Abstract 3261: Plasma whole-genome sequencing to monitor pancreatic cancer	41
Abstract 5761: Unbiased phosphoproteomic and metabolic profiling in WT and KRAS mutant colorectal cancer cells reveals molecular interplay between protein regulation and metabolic rewiring	41
Abstract 4772: AI-guided engineering and preclinical development of biparatopic anti-DLL3 antibody-drug conjugates (ADCs)	41
Abstract 1273: Advancing precision oncology: Development and utilization of breast cancer PDX models for in vivo drug discovery	40
Abstract 2074: MALDI-ICC: a new tool for high-plex, multiomic profiling of single cells for cancer research and cancer therapy	40
Abstract 3887: Clonal expansion in the bile duct associated with primary sclerosing cholangitis	40
Abstract 3731: The role of dietary patterns and microbiome composition in colorectal cancer survival: The ColoCare Study	40
Abstract 3849: Pygo2 deletion stimulates tertiary lymphoid structure formation and forms the cornerstone for a quadruple combination immunotherapy of prostate cancer	40
Abstract 3727: Physical activity patters according to demographic, social, and clinical correlates among breast cancer survivors	40
Abstract 5690: Targeting MET activation in CDH1 deficient diffuse gastric cancer with peritoneal metastases	40
Abstract 3688: Correlation between natural killer cell sensitivity and epithelial mesenchymal transition morphology: A cell morphology based screening for NK cell susceptible tumor cells	39
Abstract 3371: Gene deletions in estrogen receptor positive HER2-negative breast cancer are associated with worse outcome than predicted by diagnostic-grade gene expression assays	39
Abstract 3655: Leveraging alternative AIML technologies to identify predictive biomarkers for chemotherapy selection: An analysis of the COMPASS trial evaluating chemotherapy response in advanced PDAC	39
Abstract 47: Optimizing in vivo establishment of hormone receptor-positive breast cancer patient-derived xenografts for therapeutic assessment	39
Abstract 294: TFEB nuclear persistence predicts sensitivity to lysosomal inhibition in therapy-induced senescent thyroid cancer cells	39
Abstract 2873: Preclinical development of SMP-656: An eribulin-SuperHydraTM linker based ADC	39
Abstract 1510: Glutathione-oxidation of ovarian tumor deubiquitinase-1 promotes lung adenocarcinoma survival through stabilizing system xc-	39
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA)	39
Abstract 424: Chromosomal instability leads to EGFR-TKI refractoriness via cGAS-STING activation in EGFR-mutated non-small cell lung cancer	39
Abstract 1120: Baseline biomarker analyses of patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC) from the phase 3 CodeBreaK 300 study	39
Abstract 7218: Preventive use of trilaciclib in Chinese patient with extensive-stage small cell lung cancer (ES-SCLC) receiving chemotherapy: A multi-center, single-arm, observational real-world study	38
Abstract 7085: Analysis of gene expression pattern of glycosphingolipid synthases using tumor tissues from breast cancer patients to identify key targets for early diagnosis and protection of recurren	38
Abstract 7502: Radiation-induced transcriptomic reprogramming of mesenchymal glioblastoma stem cells reveals key pathways and potential targets	38
Abstract 679: Orthogonal confirmation using the Pacbio®two step universal adapter amplicon protocol to validate a comprehensive genomic profiling assay for hematologic malignancies	38
Abstract 7210: Predicting drug response heterogeneity in AML: novel AI-enabled proteomics model for a prospective clinical trial	38
Abstract 6676: Spatial proteomics and AI-driven analysis uncover therapeutic landscapes within the glioblastoma microenvironment	37
Abstract 2386: Evaluating ABCC1 as a potential prognostic biomarker in laryngeal cancer health outcomes	37
Abstract 6703: Rg002: An mRNA-LNP-based immunotherapy targeting HPV-16/18-related malignancies	37
Abstract 7274: Structural variant signature discovery across >8,000 TCGA whole genomes using QuantHDP	37
Abstract 4956: Spatial and vascular microenvironmental features predict tumor-infiltrating lymphocyte expansion in glioblastoma	37
Abstract 7736: Rare EGFR cis compound L833V/H835L mutation in non-small cell lung cancer is oncogenic and a therapeutic target of EGFR tyrosine kinase in	37
Abstract 6708: Neoadjuvant pembrolizumab with therapeutic DNA vaccine reshape intratumoral immunity in a phase 2 trial of HPV-positive HNSCC	37
Abstract 7897: Novel Rho-GTPase regulatory protein gene family variants are frequent and associate with poor survival in patients (pts) with acute myeloid leukemia (AML)	37
Abstract 4300: IND-enabling development of a novel STING agonist, IMGS-203, for the treatment of glioblastoma	37
Abstract 5243: Profiling of peripheral LAG-3+CD8+ T cells: An immune cell population associated with immunotherapy resistance	37
Abstract 7276: Understanding cutaneous immune-related adverse events at single-cell resolution	37
Abstract 4880: An in-vitro vascularized micro-tumor model of cervical cancer	37
Abstract 4669: Label free identification of cancer cell death pathways via holotomography and deep learning as an early pharmacodynamic biomarker	36
Abstract 4170: An AI-driven multimodal workflow for enhancing late-phase clinical trial outcome prediction	36
Abstract 4103: Dynamic co-mutation patterns and therapeutic implications in BRAF-altered malignancies: Evidence from AACR Project GENIE	36
Abstract 7531: Autoimmunity in a Dish: A 3D human orbital fibroblast platform for inflammatory biomarker discovery and fibrotic stromal biology	36
Abstract 4146: Melanocytic transcriptional state is an independent marker of survival in metastatic melanoma	36
Abstract 4820: TIM-3 as a prospective target to eliminate pancreatic cancer stem cells	36
Abstract 6488: Dual targeting of PARP and RAS enhances antitumor activity in pancreatic cancer	36
Abstract 1683: Enhancing therapeutic efficacy and overcoming resistance with a novel dual-payload antibody-drug conjugate technology	36
Abstract 3269: Rebalancing systemic and cellular energy dysmetabolism in Chronic Lymphocytic Leukemia through exercise training	36
Abstract 4704: Disruption in cholesterol homeostasis by free fatty acid promote colon cancer by modulating CCL20	36
Abstract 5588: A next-generation tri-specific T cell engager targeting CDH17 with 4-1BB co-stimulation for the treatment of gastrointestinal cancers	36
Abstract 5927: Integrative analysis of EMT and hippo pathway activity in gastric cancer peritoneal metastasis	36
Abstract 6090: Characterization of eIF3h as a driver of triple negative breast cancer progression	35
Abstract 5949: Targeting SLC25A13 sensitizes melanoma to treatment and reduces tumor aggressiveness via metabolic rewiring	35
Abstract 7245: Mechanistic dissection of ABI1 as DNA-binding transcriptional regulator in cancer cells	35
Abstract 2818: Preclinical Characterization of ALG-094295, a highly potent and orally bioavailable small molecule PD-1/PD-L1 inhibitor targeting dimerization, internalization and degradation of PD-L1	35
Abstract 3498: Improving the utility of the single-cell pediatric cancer atlas through updated cell type annotations, CNV inference, and visualization tools	35
Abstract 4245: The Immune strategies to convert cold to hot tumors and overcome resistances	35
Abstract 7261: Comprehensive multi-omics profiling reveals molecular heterogeneity and developmental signatures in solid pseudopapillary neoplasm of the pancreas	35
Abstract 6082: IFNα polarizes granulocytic MDSCs from neutrophils by inducing protein translation	35
Abstract 4637: Alpha-particle radiotherapy combined with anti-CTLA-4 synergistically overcomes radioresistance and induces local and systemic antitumor immunity in PDAC	35
Abstract 4969: Automated multiomics assay with over 100 biomarkers for in-depth spatial profiling of the tumor microenvironment in multiple cancer types	35
Abstract 3667: Neohesperidin dihydrochalcone: A novel natural inhibitor of ferroptosis	35
Abstract 5176: Selective degradation of SMARCA4 as a therapeutic strategy in SMARCA4 driven cancers	34
Abstract 2928: KRAS inhibition-induced GSDME-mediated pyroptosis and its augmentation by LAT1 inhibition in KRAS-mutant lung cancer	34
Abstract 1784: Mechanistic characterization of (Z)-endoxifen in ESR1-mutant and endocrine-resistant breast cancer	34
Abstract 3540: KRAS allelic imbalance reshapes tumor evolution through selective clonal outgrowth and chromosomal instability in NSCLC	34
Abstract 5559: Spatial neuroimmune crosstalk driving perineural invasion in head and neck squamous cell carcinoma	34
Abstract 6424: MICRO-TAG® cell target engagement redefines GPCR drug discovery with functional relevance	34
Abstract 5784: Discovery of FX-111, a first-in-class heterobifunctional degrader of transcriptionally active androgen receptor (ARON), to treat patients with AR-driven prostate cancer	34
Abstract 6058: Tumor suppressor gene inactivation shapes the landscape of EGFR-mutant lung adenocarcinoma progression with therapeutic implications	34
Abstract 3107: CWH43 emerges as a novel therapeutic target linked to chemoresistance in colorectal cancer	34
Abstract 1687: Engineering multi-specific and multi-payload ADCs to address tumor heterogeneity and drug resistance	34
Abstract 2302: Prognostic biomarkers associated with the progression of cervical premalignant lesions to cancer: A scoping review	34
Abstract 7464: Inhibiting interferon-gamma-stimulated melanoma progression by disrupting the crosstalk between nNOS/NO and COX-2	34
Abstract 5794: Leveraging E2 ligases for induced proximity and modulation of novel cancer-relevant targets and neosubstrates	34
Abstract 7087: Optimizing the linker of venetoclax-artemisinin conjugates to improve water solubility and antileukemia effects	34
Abstract 3120: Using genome wide CRISPR screening to identify synthetic lethal targets for overcoming chemoresistance in rhabdomyosarcoma	34
Abstract 1751: Deletion of the DACH1 gene tumor suppressor increases replication fork stress, epithelial mesenchymal transition and sensitivity to WEE1 kinase inhibitors in prostate cancer	33
Abstract 1528: AZD5851, a TGF-β-resistant GPC3 CAR-T cell product, prolongs animal survival times in patient derived orthotopic xenograft models of medulloblastoma and atypical teratoid rhabdoid tumor	33
Abstract 5104: Cost-effectiveness analysis of integrating multi-cancer early detection into current cancer screenings in the United States	33
Abstract 5573: Novel ASPORIN/CRABP2 axis drives cell-state plasticity from adenocarcinoma to neuroendocrine-like prostate cancer	33
Abstract 1713: STRO-006: An Integrin beta-6-targeting ADC demonstrates favorable safety profile and potent antitumor activity in preclinical solid tumors	33
Abstract 7369: Hypofractionated prostate and pelvic nodal radiotherapy with androgen deprivation therapy for high-risk prostate cancer: A retrospective analysis of oncologic outcomes and toxicity	33
Abstract 4307: Pregnancy-inspired DNA nanocarriers reproduce a cGAS-driven pro-inflammatory monocyte phenotype	33
Abstract 6408: Unlocking the unlockable: AS-MS for swift hit identification against challenging targets	33
Abstract 5941: Large-scale analysis reveals distinct molecular subtypes in real-world gastric cancer data	33
Abstract 3176: Tumor-selective regression through MUC16-guided DR5 (TNFRSF10B) clustering by the bispecific anti-MUC16×anti-DR5 antibody IMV-M™	33
Abstract 5218: Leveraging a PARP inhibitor as neuroprotection against chemotherapy induced cognitive impairments	33
Abstract 4331: ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile	32
Abstract 6181: Development of a clinically relevant in vitro model of ETMR and implications for drug efficacy studies	32
Abstract 7941: The Sphk1-B cell axis as a targetable immunoregulatory pathway in cancer	32
Abstract 5164: Exploration of novel E3 ligase to support targeted protein degradation drug discovery	32
Abstract 1582: Integrative functional and multi-omics profiling reveals divergent natural killer cell responses and tumor cell plasticity in breast and ovarian cancer	32
Abstract 1488: Structure-guided dual targeting of EZH2 and dopamine D1 receptor suppresses TNBC growth and metastasis	32
Abstract 1612: Novel CD3 binders enable T cell engagers with potent tumor control, limited cytokine release, and safe pairing with co-stimulation	32